Kanglin Biotech (Hangzhou) Co. LTD   Report issue

For profit Phase 1
Founded: Hangzhou China (2015)
Status: Defunct (2021)

Organization Overview

First Clinical Trial
2018
NCT03517631
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Kanglin Biotech (Hangzhou) Co. LTD | R&D Kanglin Biotech

Active Ingredients

Drugs in Phase 1 Trials (3)

busulfan (Myleran) (1 trial)

kl002 (1 trial)

shRNA-modified CD34+ cells (1 trial)

Drugs in Other Trials (1)

kl003 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

HIV Infections (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 4